Last reviewed · How we verify
Metformin-GLP-1 Receptor Agonist
At a glance
| Generic name | Metformin-GLP-1 Receptor Agonist |
|---|---|
| Also known as | Metformin-exenatide/liraglutide Therapy |
| Sponsor | Xinqiao Hospital of Chongqing |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Surgical or Medical Treatment (PHASE4)
- Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome (PHASE3)
- Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs (NA)
- LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes (NA)
- The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease (PHASE2)
- Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
- Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity (NA)
- Metabolic Surgery for Atrial Fibrillation Elimination (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metformin-GLP-1 Receptor Agonist CI brief — competitive landscape report
- Metformin-GLP-1 Receptor Agonist updates RSS · CI watch RSS
- Xinqiao Hospital of Chongqing portfolio CI